Feiyu Chen
Zhangfeng Zhong
Hor Yue Tan
Chi-wing Tan
Ning Wang
Yibin Feng- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
The potential values of Chinese herbal formulas in treating various diseases are well known. In addition to more than 2,000 years of history, herbal medicine is appreciated for its remarkable efficacy in a lot of cases, which warrants a role in public health care worldwide, especially in East Asian countries. Liver cancer is the second most fatal cancer across the world. Recent studies have extensively investigated the chemical profiles and pharmacological effects of Chinese herbal medicine formulas on liver cancer. Either through observational follow-up or experimental studies, multiple herbal formulas have benefits implicated in the management of liver cancer. However, complex composition of each formula imposes restrictions on promoting clinical practice and global recognition. Therefore, understanding the mode of action of Chinese herbal medicine formulas in depth may offer sufficient evidence for their clinical use. This review highlighted the chemical characteristics and molecular mechanisms of actions of prominent Chinese herbal medicine formulas and summarized the correlated findings on the potential use in liver cancer treatment. At last, the present progresses of Chinese herbal medicine formulas in the perspective of clinical trials are discussed.
Introduction
Liver cancer is highly fatal, with an estimation of 841,000 new cases and 782,000 new deaths for liver cancer that occurred around the world in 2018 (Bray et al., 2018). In contrast to any other cancers, liver cancer incidence and mortality are both increasing at a faster pace by almost 3% per year (Siegel et al., 2017). As of now, liver transplantation, image-guided ablation, and chemoembolization are state-of-the-art therapeutic modalities in practice. Even so, Asian countries are still undergoing the rapidly increasing cancer burden due largely to immense scale of population as well as less abundant medical resources. Compared to the United States, China has relatively poorer survival rate, with 40% higher cancer-related death among patients diagnosed with cancer (Feng et al., 2019).
Various forms of complementary and alternative medicine have been studied and practiced to deal with cancers or ailments (Barnes et al., 2008). A wide spectrum of medicinal herbs as well as their natural constituents or extracts has been demonstrated to possess anticancer properties with involvement of possible mechanisms including cell cycle arrest, cell apoptosis induction, inflammation suppression, immune modification, and angiogenesis inhibition. For example, Coptidis chinensis Franch (Huanglian) extract and its main active compound, berberine, were revealed antineoplastic activity via inducing cell cycle arrest and cell apoptosis, as well as inhibiting metastasis and angiogenesis (Wang et al., 2015b), partly involving tumor suppressor p53 and miR-23a pathway (Wang et al., 2014). Moreover, targeting the hypoxia-inducible factor 1 signaling pathway is a key antiangiogenic mechanism behind cancer treatment with the formula Pien Tze Huang, as well as famous compounds such as curcumin, ginsenosides, and baicalein (Hong et al., 2019). Based on the fact that Danshensu is the major bioactive constituent of Salvia miltiorrhiza Bunge (Danshen), novel compounds were designed as multidrug resistance reversal agents, and Danshensu-tetramethylpyrazine conjugate was observed to overcome multidrug resistance via simultaneously inhibiting P-gp activity and regulating metabolic process (Zhou et al., 2019).
Nevertheless, with 2,000-year empirical evidence, Chinese medicine has always been characterized with holistic perspective and syndrome differentiation. Based on these principles of diagnosis and treatment, cancer is rather believed as the “cumulative toxicity” of internal organs that combines several patterns of syndrome (Liu et al., 2015). The application of herbal formulas is being well recognized for those multicomponents in confronting complexity of cancer. More so, formulas are favorable in cancer complications management, leading to less function impairment, pain alleviation, sleep improvement, and depression remission (Tao et al., 2015b). In the Chinese Pharmacopoeia (2015 edition), a total of 25 formulas are documented with antineoplastic efficacy, featuring with Qi invigorating, heat clearing and detoxifying, blood activating, and stasis removing, as well as phlegm removing (Huang et al., 2019). Among them, Qi tonifying and detoxification are two main strategies for liver cancer therapy. Combining herbal medicines with diverse functions could synergistically benefit cancer patients (Figure 1).
Figure 1 The roles of Chinese herbal medicine formulas in liver cancer treatment.
To better understand molecular mechanisms whereby Chinese herbal medicine formulas exert their antineoplastic efficacies in liver cancer as well as current status of formulas in clinical practice, database retrieval was conducted in PubMed and Web of Science, as well as China National Knowledge Infrastructure, with terms including liver cancer, hepatocellular carcinoma, Chinese medicine, herbal formula, and Chinese medicine herbal formula, alone or in randomized combination (Figure 2). Publications in English and Chinese were both included (Table 1).
Figure 2 The flowchart of the literatures search strategy, inclusion and exclusion criteria.
Table 1 Chinese herbal medicine formulas for liver cancer treatment.
Chinese Herbal Medicine Formulas Intervene Liver Cancer Progression
According to the principles of Chinese medicine, liver cancer is being considered the cumulative toxicity of internal organs that combines several patterns of syndrome such as Qi-blood deficiency, phlegm stagnation, blood stasis, spleen deficiency, or damp-toxin condensation. However, there is a consensus in terms of the selection of therapeutic strategy, which is to invigorate Qi and eliminate toxic pathogens (Huang et al., 2019). As more than 5,000 medicinal herbs have been documented and practiced in Asia to date, as well as the same herbs usually present disparate functions in different formulas due to interactions with each other in different combinations, a valid and successful formula normally goes through several modifications in dosage or choice of herbs. As such, clarifying the molecular mechanisms underground the anticancer action of Chinese herbal medicine formulas might shed new light on liver cancer treatment.
Ancient Herbal Formulas in Liver Cancer Treatment
Yi Guan Jian (YGJ) was established by Wei Zhixiu in Qing Dynasty. Its application in treating liver disease with liver-YIN deficiency has been well documented in Chinese medical monograph (Liu et al., 2005). With consideration that hepatoma generation may be attributed to liver-YIN insufficiency (Wu et al., 2007), YGJ has long been an optimal formula for liver cancer. Yet its tumor suppression activity is not as stable and sustained as anticipated; researchers optimized the original prescription by changing dosages of some herbs. After exposure of hepatoma Bel-7402 cells to modified YGJ, considerable decline in cell proliferation was observed, and the inhibitory action was further reported to be correlated with the induction of anoikis and p38 phosphorylation (Hu et al., 2011). The formula named San Huang Xie Xin Tang (SHXXT) is made up of three herbs, which are Coptis chinensis Franch (Huanglian), Scutellaria baicalensis Georgi (Huangqin), and Rheum palmatum L. (Dahuang). Their individual effects to restrain hepatocellular carcinoma have been demonstrated to modulate cell cycle or apoptotic profiles (Chang et al., 2002; Lin et al., 2004; Chan et al., 2006; Lu et al., 2007). Researchers analyzed gene profiles of HepG2 cells after exposure to SHXXT, indicating that SHXXT displayed antiproliferation pattern via p53 signaling and DNA damage (Cheng et al., 2008). Huanglian Jiedu decoction (HJD) is a canonical herbal formula that has been used for heat-damp–related diseases since its inception 1,300 years ago. Recently, its curative effect in several types of cancer is appreciated in the Asian community. Chinese medical practitioners have postulated HJD as a regimen for cancer treatment. Previous reports identified the tumor suppression of hepatocellular carcinoma after HJD administration, and further investigation indicated that eukaryotic elongation factor 2 might be a new target of the formula in attenuating cancer progression (Wang et al., 2015a). Zuo Jin Wan (ZJW) is a well-known drug pair composed of C. chinensis Franch and Fructus rutaecarpa Benth (Wuzhuyu), which was prescribed to remove heat and dampness from liver. Recent works have identified antineoplastic activity of ZJW in several types of tumors including gastric cancer (Tang et al., 2012), colorectal cancer (Sui et al., 2013), breast cancer (Du et al., 2013), and liver cancer (Chao et al., 2011; Chou et al., 2017). The mode of action underlying the antiproliferation effect of ZJW on these malignancies involved the induction of mitochondria-dependent apoptosis (Xu et al., 2014). Gansui Banxia Tang (GBT) is proposed and practiced dating back centuries by Zhang Zhongjing, who has been a Chinese medical sage of considerable standing. The formula has been used for treatment of effusion of pleural, peritoneal, pericardial, and cranial cavities and intestinal tuberculosis, as well as gastrointestinal inflammation. In modern times, it was shown that it may be effective in some malignancies and cancerous ascites, such as hepatocellular carcinoma and esophageal cancer (Xia, 1989; Song, 1993), yet the pharmacological mechanism behind the anticancer effect has not been fully elucidated. Euphobiae kansui S. L. Liou ex S.B.Ho (Gansui) and Glycyrhiza glabra L. (Daji), two herbs in GBT, which are traditionally regarded as prohibited combination in “18 antagonisms,” are, however, intriguingly included in the same formula. In order to illuminate the synergy as well as the action mechanism of the ingredients on hepatocellular carcinoma, Zhang and colleagues developed a comprehensive system of integrating disease-specific and drug-specific network, which revealed the associations of GBT ingredients with their putative targets, concurrently with hepatoma-related pathways. Moreover, further experiments showed that Hsp90a, ATP1A1, and STAT3 proteins might be targeting molecules in tumor repression (Zhang et al., 2014). Shuihonghuazi formula (SHHZF) is made up of four medical herbs including Polygonum orientale L. (Shuihonghuazi), Ophicalcitum Serpentine (Huaruishi), Coix lacryma-jobi L. (Yiyiren), and Imperata cylindrica L. Raeusch (Baimao). Over the past 30 years, growing clinical experiences have demonstrated considerable antineoplastic ability of SHHZF in liver cancer patients (Lee et al., 2008; Zhou et al., 2012). Since the mode of action remains obscure, researchers have adopted the metabolomics method to facilitate the understanding of metabolomic characteristics related to its function. The study indicated metabolic profiles involving mediation of phosphatidylethanolamine N-methyltransferase, lysophospholipase D, methylenetetrahydrofolate reductase, and lysophospholipase are responsible for the antitumor effect (Bao et al., 2017).
As we know, clinical employment of some formulas remains unsatisfactory due in part to extraction approach barrier. Successful discovery of artemisinin by Nobel Laureate Tu Youyou exemplifies the fact that inappropriate extraction method may undermine effectiveness. Screening for optimal extraction methods of herbal formulas may help to achieve better therapeutic outcome. Rather than the conventional method utilizing water to extract active constituents from herbal formulas, present works place much focus on extraction using different polarity solvents (Cao et al., 2013). Thus, Chinese herbal medicine formulas may deserve more attention in the field.
Nascent Herbal Formulas in Liver Cancer Treatment
Beyond ancient formulas generally used in clinical practice, a wealth of nascent formulas has been used over the past few decades, and the relevant pharmacological actions have been investigated. Fuzheng Yiliu decoction (FYD) is a polyherbal formula consisting of Qi-blood–tonifying and heat toxin–clearing herbs. Human hepatocellular carcinoma HepG2 and MHC97H cells were exposed to FYD, and the findings showed inhibitory actions of FYD in tumor progression, invasion, and migration (Peng et al., 2018). Another formula composed of eight herbs is an empirical prescription initiated by a Chinese medical physician from Shaanxi province. The formula was demonstrated to reverse epithelial–mesenchymal transition in HepG2 cells, by which invasion and migration capacities were remarkably blocked (Fang et al., 2019). Matrix metallopeptidases (MMPs) are a family of proteases known to degrade extracellular matrix proteins, which in turn renders the reduction in cell adhesion, following the disruption of cellular processes. Upregulation of MMPs has been well documented in multiple types of tumor (Shay et al., 2015). Fuzheng Jiedu Tongluo formula is made up of 10 herbs and was reported to restrain invasion and migration abilities by decreasing the expression levels of MMP-2 and MMP-9 (Zhang et al., 2017). Based on clinical medications and related studies, Yanggan Jiedu Sangjie formula (YJSF) was established for hepatoma treatment. In present study, they evaluated the anticancer potential of YJSF on suspension human hepatocellular carcinoma Bel-7402 cells. YJSF inhibited anchorage-independent growth and induced caspase-mediated anoikis in Bel-7402 cells, which may be related to ROS generation and PTK2 downregulation (Hu et al., 2018). Several lines of evidence have identified the hepatoprotective role of Astragalus membranaceus Bunge (Huangqi) and S. miltiorrhiza Bunge (Roxas and Jurenka, 2007). The two herbs have seen positive efficacy in both in vitro and in vivo models of liver fibrosis and hepatoma (Chan et al., 2009; Chen et al., 2011). Researchers designed a synergized formula with active ingredients extracted from the two herbs using orthogonal studies and named it CASE (Yang et al., 2008). Mechanistically, CASE modulated TGF-β/Smad signaling pathway and inhibited TGF-β–specific target gene expression in liver fibrosis and hepatocellular carcinoma, whereas the amelioration of hepatoma phenotypic hallmarks was verified (Boye et al., 2015). Herbal formula QHF is composed of three types of herbs with characteristics of clear heating (Qingrejiedu, Q), blood circulation promoting (Huoxuehuayu, H), and energy consolidating (Fuzhengguben, F). Researchers optimized the composition ratios of the formula (Tao et al., 2010), followed by the underlying mechanism of the prescription in liver cancer being investigated, which showed dramatic improvement of QHF in inhibiting migration and invasion activities in hepatic carcinoma HepG2 cells (Chen et al., 2016).
Chinese Herbal Medicine Formulas Inhibit Liver Metastases
Cancer metastasis is one of the major barriers to successful management of carcinomas. As a critical hub in the body, the liver is involved in numerous physiological processes (Trefts et al., 2017). With two large blood vessels connected to the liver, it is a main site of metastatic disease from gastrointestinal tract, particularly colonic, gastric, and pancreatic malignancies. Reciprocal interactions between tumor cells and adjacent normal cells are implicated in hepatic metastases. Drugs that reverse or attenuate such intercellular communication will be in favor of suppressing tumor metastasis. Because diverse cross-communications occur in cancer metastasis, Chinese medicine holds the holistic perspective that might be beneficial in metastasis suppression. In fact, some formulas have been investigated in dealing with liver metastasis. A well-known formula named Pien Tze Huang (PZH) has been demonstrated effective in the management of several types of tumors (Wan et al., 2017; Chen et al., 2018). Recent work reported that PZH could not only repress colorectal tumor growth, but also exert anti–liver metastasis through the inhibition of epithelial-to-mesenchymal transition (Lin et al., 2015). Moreover, upregulated miR-16 expression was observed in its anti–hepatocellular carcinoma activity (Qi et al., 2017). Herbal medicine is popular not only in China, but also in Korea with its development based on Chinese medicine. Ka-mi-kae-kyuk-tang (KMKKT) is a formula that comprises 10 oriental herbs. Korean researchers reported with bench experiments and preclinical trials that KMKKT inhibited invasiveness of mouse colon cancer 26-L5 cells, and liver metastasis was less likely to occur in mice model (Lee et al., 2006). Weichang'an (WCA) is a herbal formula prescribed by practitioners, and the principal functions are spleen invigorating and heat clearing. Previous efforts have identified that patients with gastric (Zhao et al., 2010; Xu et al., 2013) or colon cancer (Gu et al., 2006) could benefit from WCA, whereas recent work showed positive efficacy of WCA in colorectal tumor with hepatic metastasis, in which decreased expressions of β-catenin and MMP-7 may be involved in the inhibitory action (Tao et al., 2015a). Pancreatic cancer is a common digestive system disease. A seven-herb formula named QYHJ has been used to treat pancreatic cancer, and patients receiving it reported prolonged survival time. Several scholars established the model of pancreatic cancer with liver metastasis using nude mice and found that QYHJ suppressed liver metastasis from pancreatic tumor, at least by reversing epithelial-to-mesenchymal transition (Zhang et al., 2013).
Chinese Herbal Medicine Formulas Serve as Antiviral Agents to Prevent Liver Cancer
The infection of hepatitis viruses accounts for the majority of liver cancer occurrence. The most predominant contributor to this high burden is the dissemination of chronic infections with hepatitis B virus (HBV) and hepatitis C virus. Infection of hepatitis viruses can progress toward liver cirrhosis, which is tightly associated with hepatocellular carcinoma (Feng et al., 2019).
Hepatocellular carcinoma is characterized as the most prevalent cancer in China in recent decades. Recent decline in incidence has been partly attributed to effective prevention and suppression of hepatitis viruses (Sherman, 2008). Chinese medicine has long been used to diminish viruses and bacteria, which are risk factors for many ailments and diseases. On account of effective and multitargeting actions against viral infections, herbal formulas are lately receiving increasing attention. Dahuang Zhechong formula (DZF) has been used for the treatment of chronic hepatitis B, but its efficacy in liver fibrosis is conflicting. For this purpose, researchers made a meta-analysis for the effect of DZF on liver fibrosis, suggesting that DZF as adjuvant treatment could reverse liver fibrosis in patients with HBV infection, and robust conclusion was reached that antifibrotic effect might be a potential benefit of DZT. Nevertheless, for long-term clinical use in liver cancer patients with HBV infection, more investigations should be carried out in laboratory and clinical trials (Wei et al., 2015). The herbal formula has capacity of being anti-HBV, namely, ZYD. Its effect on the biological behavior of liver cancer was evaluated using hepatocellular carcinoma SMMC-7721 cells, displaying that ZYD could considerably attenuate migratory and adhesion abilities of hepatoma cells by a dose-dependent manner. Further investigation demonstrated the deregulations of Snail, MMP-2, and MMP-9 expression at nucleic acid level (Guo et al.). Recent work from a Korean group newly developed an oriental formula, KCT-01, which is extracted from Artemisia capillaris Thunb (Yinchen), Sanguisorba officinalis L. (Diyu), and Curcuma longa L. (Jianghuang). They reported that KCT-01 is able to suppress HBV replication and inflammatory cytokine production with low risk of toxicity either in cell or in animal models, indicating the antiviral potential of using KCT-01 alone or in combination with entecavir (Kim et al., 2018).
Collectively, there is currently no eradication cure for hepatitis viruses because of the characteristic obstacle that viral minichromosome covalently closed circular DNA persistently exists in infected subjects (Charre et al., 2019). To some extent, Chinese herbal medicine formulas represent an alternative choice for antiviral therapy. In this situation, a range of liver cancer incidence could possibly be averted.
Complementary Therapy for Liver Cancer Management
To our knowledge, curative outcome of current advanced therapeutic modalities including liver transplantation, image-guided ablation, and chemoembolization remains suboptimal in liver cancer patients due partly to multiple side effects. In this case, Chinese medicine herbal formulas have gained increasing attention because of fewer adverse effects and less toxicity to adjacent cells or tissues (Li et al., 2019; Zeng et al., 2019). Herein, several relevant examples are illustrated to show adjunctive and complementary roles of formulas in the treatment of malignancies. Shen-Ling-Bai-Zhu powder (SLBZP) is a classic herbal remedy that has been used in the management of gastrointestinal carcinoma for a long period of time. A comprehensive analysis was conducted to determine the precise role of SLBZP in hepatocellular carcinoma, which identified the antitumor property of the formula in hepatoma. More than that, compared to patients simply receiving chemotherapy, hepatoma subjects synchronously undertaking the formula reported better curative outcome, indicating the therapeutic merit of SLBZP coupled with chemotherapy for hepatoma. The mechanism behind involved descending levels of tumor growth promoters and apoptotic suppressor proteins (Xi et al., 2016). JDF granule comprised detoxifying endotoxic herbs and has been commonly used in Chinese clinics, and some compositions of the formula have demonstrated cytotoxic activity against several hepatoma cells such as BEL-7402 and SMMC-7721 (Xu et al., 2010). As hepatocellular carcinoma is an intricate disease with multivariate etiology, a synergistic strategy that Chinese herbal medicine is combined with modern therapeutic modalities has acquired extensive attention. Lately, a retrospective case study was performed to analyze the combinate employment of transcatheter arterial chemoembolization (TACE) with JDF for hepatocellular carcinoma therapy. The conclusion could be made that JDF granule considerably improved the prognosis of hepatocellular carcinoma patients undertaking TACE (Yu et al., 2009). PHY906 is a formula that has long been used for 1,800 years to treat distressing conditions of the gastrointestinal disorder. In the recent past, preclinical and early-phase clinical trials of PHY906 coupled with chemotherapy in patients with advanced hepatocellular carcinoma (Yen et al., 2009), pancreatic cancer and other gastrointestinal malignancies (Saif et al., 2010) have yielded promising results. Ciji Hua'ai Baosheng granule (CHBG) is an empirical formula originated by a Chinese medical practitioner from Fujian. The herbal compositions possess multiple capacities of reinforcing Qi, removing blood stasis, and dissipating phlegm, which have been confirmed to effectively alleviate symptoms of cancer patients. The group investigated the effect of CHBG on general health and survival time in H22 mice model with chemotherapy treatment, showing that CHBG obviously contributed to survival time of mice bearing subcutaneous transplanted tumor or ascitic tumor (Xi et al., 2014). One step further, CHBG was identified as complementary therapy for patients undertaking chemotherapy by improving immune function and attenuating side effects (Xi et al., 2018). It is well known that exercise is favorable in overcoming and preventing ailments and diseases; the combined application of exercise and herbal formulas has not yet been largely studied. Intriguingly, researchers investigated the possibility of Songyou Yin (SYY) in parallel with swimming in liver cancer treatment. SYY is a five-herb formula that was demonstrated to exert enhanced effect on tumor suppression and metastasis inhibition. Combined use of SYY and swimming exercise showed protective effects against liver cancer in animal models (Zhang et al., 2016).
Clinical Trials of Chinese Herbal Medicine Formula Offer Options for Liver Cancer Treatment
Extensive laboratory experiments have been conducted to explore the mechanisms of action by herbal formulas in liver cancer management. Nevertheless, herbal formulas have not yet been incorporated into conventional health care due to a series of obstacles, such as safety concerns, quality control of herbs, and evidence from clinical trials. Systematic and rigorous clinical evaluation are essential to transform oriental herbal practices into evidence-based prescriptions, which could provide an insight into the application of herbal formulas in the management of hepatic cancer (Yu et al., 2009; Du et al., 2010).
As stated above, in contrast to classical herbal formulas, growing nascent formulas have been introduced and prescribed by Chinese medicine practitioners. To observe clinical effectiveness of Yanggan Huayu KangaiSan (YHKS) on advanced primary liver cancer, 25 patients were recruited and orally received the formula for two courses. After treatment, glutamate aminotransferase, aspartate aminotransferase, serum total bilirubin, serum α-fetoprotein descended obviously; other clinical complications including pain relief was improved, implying that YHKS could improve life quality of patients (Zhao et al., 2011). To investigate the clinical efficacy of Danzhi Xiaoyao San (DXS) plus ablation on liver tumor, a study comparing microwave ablation treatment with combinate use of ablation and DXS found significant differences. Within 80 cases, patients who took oral DXS reported reduced α-fetoprotein, as well as less incidence of adverse reactions (Zhu et al., 2017). Transcatheter hepatic arterial chemoembolization is one of the efficient therapeutic avenues for hepatic tumor, yet postoperative syndrome is a tough problem in most cases. Researchers recruited 60 patients with hepatic cancer, who had been diagnosed as postoperative syndrome prior to recruiting. After receiving Dachaihu decoction, a premier choice by medical sage Zhang Zhongjing for soothing liver and eliminating pathogens, adverse reactions including fever, abdominal pain, nausea and vomiting, and insomnia were found alleviated, which warrant further investigations and clinical practices (Wang et al., 2019). Around the same time, another study reported the curative outcome of combinatory employment of Dachaihu decoction and another canonical formula Liujunzi decoction, in the management of postoperative syndrome. The finding showed that patients who received combinatory formulas had better scores in life quality and liver function (Zhang, 2019). In addition, a recent work reported Sijunzi decoction, a tonic prescription documented in “Prescriptions People's Welfare Pharmacy,” could improve immune function of patients who received TACE as well as relieve their adverse reactions (Song and Wu, 2017).
Despite surgery is an effective modality for hepatic cancer patients with no extrahepatic metastasis, the postoperative surgery still negatively influences patients' life quality. Scholars recruited 128 postoperative patients, and half of the cases received Sijunzi decoction, while the remaining received placebo. They found that the recurrence rate in the treated group was reduced compared to placebo group, and the mechanism possibly involved regulation of T lymphocytes and natural killer cells (Chen et al., 2017). Interestingly, beyond combinatory use of a couple of formulas, Tui-na (Chinese massage) was also employed with classic formulas. Simo decoction in combination with acupoint massage exerted significant therapeutic efficacy in recovery of gastrointestinal function of primary liver cancer patients (Li, 2019).
Based on clinical knowledge, cancer patients are prevalently living with cancer pain, leading to limitations in daily activity. Recognizing cancer-induced pain and initiating specialist management are important for patients' welfare. Hedyotis diffusa Willd. is the principal component of the formula with abilities of clearing heat and detoxicating, promoting circulation, and removing stasis. In a recent observational study of 80 patients with cancer, patients who received H. diffusa Willd. Detoxification Spleen Prescription (HDSP) were found to have lower incidence of pain (Cai and Liao, 2017). Shuangbai powder has been an option in promoting blood circulation, removing blood stasis, reducing swelling, and relieving pain; current advice is therefore to use Shuangbai powder in cancer pain treatment. However, extensive evidence from clinics indicated modified Shuangbai powder was preferred when the original formula failed to relieve pain. An observational study of 90 patients showed that those applied modified Shuangbai powder reported consistent pain relief in comparison with patients applying placebo (Liu et al., 2016). There are many analgesics of first-line management, and pain relief could be observed immediately, but the effectiveness could not last for a longer time; also, adverse effects have been reported such as gastrointestinal damage (Ruchita et al., 2017). Xiaotongsan, an empirical formula for external use, was practiced for years by practitioners to treat cancer-induced pain. It could enhance efficacy of conventional drug morphine through multiple targets including improvement of immune function and repression of metastasis. That said, herbal formulas could be employed coupled with first-line management of refractory pain triggered by malignant cancer (Shen et al., 2014). Taken together, on the basis of laboratory and clinical evidence-based investigations, Chinese herbal medicine formulas might have potential as latent therapeutic alternatives for liver cancer treatment.
Conclusion
Extensive evidence has highlighted the clinical application of Chinese herbal medicine formulas in cancer therapy. For liver cancer treatment, Chinese herbal medicine formulas improve the curative outcome whereby multicomponent and thereby multitarget against complex symptoms in liver cancer. Moreover, because current chemotherapy or radiotherapy leads to dose-limiting toxicities and substantial side effects, various functions as well as modifiable herbal compositions of the formula ensure synergistic effects and even fewer side effects. However, complexed and modifiable herbal constituents are exactly the major hurdle to clarify the underlying molecular mechanisms. On the other hand, there are cases that Chinese herbs may be harmful to the human body and cause serious toxicity when taken excessively or under inappropriate circumstances. It is also the complexed and unprecise constituents that have to take the large blame for incidences. Therefore, further optimization and large-scale validation are always imperative in order to improve the precision and safety of Chinese herbal medicine formulas used in liver cancer management. Attempts to develop herbal formulas into stable and potent modalities may offer options of considerable merit for global health care.
Author Contributions
FC and ZZ retrieved the data and draft the manuscript. HT, WG, and CZ retrieved the data. C-WT, SL, and NW revised the manuscript. YF initiated the idea and drafted the manuscript.
Funding
This research was partially supported by the Research Council of the University of Hong Kong (project codes: 104004092 and 104004460), Wong's donation (project code: 200006276), a donation from the Gaia Family Trust of New Zealand (project code: 200007008), the Research Grants Committee (RGC) of Hong Kong, HKSAR (Project Codes: 740608, 766211, 17152116 and 17121419) and Health and Medical Research Fund (Project code: 16172751).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Bao, Y., Wang, S., Yang, X., Li, T., Xia, Y., Meng, X. (2017). Metabolomic study of the intervention effects of Shuihonghuazi Formula, a Traditional Chinese Medicinal formulae, on hepatocellular carcinoma (HCC) rats using performance HPLC/ESI-TOF-MS. J. Ethnopharmacol 198, 468–478. doi: 10.1016/j.jep.2017.01.029
Barnes, P. M., Bloom, B., Nahin, R. L. (2008). Complementary and alternative medicine use among adults and children: United States 2007. Natl. Health Stat. Rep., 1–23.
Boye, A., Wu, C., Jiang, Y., Wang, J., Wu, J., Yang, X., et al. (2015). Compound Astragalus and Salvia miltiorrhiza extracts modulate MAPK-regulated TGF-beta/Smad signaling in hepatocellular carcinoma by multi-target mechanism. J. Ethnopharmacol 169, 219–228. doi: 10.1016/j.jep.2015.04.013
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. doi: 10.3322/caac.21492
Cai, L., Liao, B. N. (2017). Effects of Hedyotis diffusa Willd detoxification Spleen Prescription on tumour related index and pain in patients with advanced primary liver cancer. J. Southeast Univ 36, 44. doi: 10.3969/j.issn.1671-6264.2017.01.011
Cao, Z., Lin, W., Huang, Z., Chen, X., Zhao, J., Zheng, L., et al. (2013). Ethyl acetate extraction from a Chinese herbal formula, Jiedu Xiaozheng Yin, inhibits the proliferation of hepatocellular carcinoma cells via induction of G0/G1 phase arrest in vivo and in vitro. Int. J. Oncol. 42, 202–210. doi: 10.3892/ijo.2012.1703
Chan, J. Y., Tang, P. M., Hon, P. M., Au, S. W., Tsui, S. K., Waye, M. M., et al. (2006). Pheophorbide a, a major antitumor component purified from Scutellaria barbata, induces apoptosis in human hepatocellular carcinoma cells. Planta Med. 72, 28–33. doi: 10.1055/s-2005-873149
Chan, W. S., Durairajan, S. S., Lu, J. H., Wang, Y., Xie, L. X., Kum, W. F., et al. (2009). Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture. Neurochem. Int. 55, 414–422. doi: 10.1016/j.neuint.2009.04.012
Chang, W. H., Chen, C. H., Lu, F. J. (2002). Different effects of baicalein, baicalin and wogonin on mitochondrial function, glutathione content and cell cycle progression in human hepatoma cell lines. Planta Med. 68, 128–132. doi: 10.1055/s-2002-20246
Chao, D. C., Lin, L. J., Kao, S. T., Huang, H. C., Chang, C. S., Liang, J. A., et al. (2011). Inhibitory effects of Zuo-Jin-Wan and its alkaloidal ingredients on activator protein 1, nuclear factor-kappaB, and cellular transformation in HepG2 cells. Fitoterapia 82, 696–703. doi: 10.1016/j.fitote.2011.02.009
Charre, C., Levrero, M., Zoulim, F., Scholtes, C. (2019). Non-invasive biomarkers for chronic hepatitis B virus infection management. Antiviral Res. 169, 104553. doi: 10.1016/j.antiviral.2019.104553
Chen, R., Shao, H., Lin, S., Zhang, J. J., Xu, K. Q. (2011). Treatment with Astragalus membranaceus produces antioxidative effects and attenuates intestinal mucosa injury induced by intestinal ischemia-reperfusion in rats. Am. J. Chin Med. 39, 879–887. doi: 10.1142/S0192415X11009275
Chen, T., Wang, Q., Li, Y., Huang, H., Hu, W. (2016). Chinese herbal formula QHF inhibits liver cancer cell invasion and migration. Exp. Ther. Med. 11, 2413–2419. doi: 10.3892/etm.2016.3247
Chen, Y., Hu, H., Zhang, S. J., Sun, B. G., Yang, H. Z. (2017). Effect of the Sijunzi decoction on the T lymphocyte and NK cell of the Hepatocellular Carcinoma patients with radical operation. Zhong XI Yi Jie He Gan Bing Za Zhi 27, 8. doi: 10.3969/j.issn.1005-0264.2017.01.003
Chen, X., Qi, F., Shen, A. L., Chu, J. F., Sferra, T. J., Chen, Y. Q., et al. (2018). Pien Tze Huang (片仔癀) Overcomes Doxorubicin Resistance and Inhibits Epithelial-Mesenchymal Transition in MCF-7/ADR Cells. Chin J. Integr. Med 25, 598–603. doi: 10.1007/s11655-018-2992-4
Cheng, W. Y., Wu, S. L., Hsiang, C. Y., Li, C. C., Lai, T. Y., Lo, H. Y., et al. (2008). Relationship Between San-Huang-Xie-Xin-Tang and its herbal components on the gene expression profiles in HepG2 cells. Am. J. Chin Med. 36, 783–797. doi: 10.1142/S0192415X08006235
Chou, S. T., Hsiang, C. Y., Lo, H. Y., Huang, H. F., Lai, M. T., Hsieh, C. L., et al. (2017). Exploration of anti-cancer effects and mechanisms of Zuo-Jin-Wan and its alkaloid components in vitro and in orthotopic HepG2 xenograft immunocompetent mice. BMC Complement Altern. Med. 17, 121. doi: 10.1186/s12906-017-1586-6
Du, Q., Hu, B., Shen, K. P., An, H. M. (2010). Progress in TCM pathogenesis and treatment of liver cancer. World J. Integr. Tradit. West. Med. 5, 814.
Du, J., Sun, Y., Wang, X. F., Lu, Y. Y., Zhou, Q. M., Su, S. B. (2013). Establishment of an Experimental Breast Cancer ZHENG Model and Curative Effect Evaluation of Zuo-Jin Wan. Evid Based Complement Alternat Med. 2013, 324732. doi: 10.1155/2013/324732
Fang, Y., Xiao, H. J., Li, R. T., Yang, Y., Chen, G. W. (2019). Effect of Fuzheng Kang'ai Formula on Anti-hepatoma by Reversing EMT Transformation of HepG2 Cells. China Med. Herald 25, 60.
Feng, R. M., Zong, Y. N., Cao, S. M., Xu, R. H. (2019). Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun. (Lond) 39, 22. doi: 10.1186/s40880-019-0368-6
Gu, Y., Zheng, Y. Y., Yang, J. K. (2006). Analysis of therapeutic effect of Wei Chang An in Colorectal Cancer. Liaoning Zhongyiyao Daxue Xuebao 8, 5. doi: 10.3969/j.issn.1673-842X.2006.05.001
Guo, P., Huang, H., Kang, C., Zhong, Y., Li, N., Zhang, B. (2018). Studies on the biological behavior and mechanism of human hepatocellular carcinoma cells SMMC-7721 by the traditional Chinese medicine ZYD of anti-hepatitis B virus. World Clin. Drugs 39, 306. doi: 10.13683/j.wph.2018.05.005
Hong, M., Shi, H., Wang, N., Tan, H. Y., Wang, Q., Feng, Y. (2019). Dual Effects of Chinese Herbal Medicines on Angiogenesis in Cancer and Ischemic Stroke Treatments: Role of HIF-1 Network. Front. Pharmacol. 10, 696. doi: 10.3389/fphar.2019.00696
Hu, B., An, H. M., Shen, K. P., Xu, L., Du, Q., Deng, S., et al. (2011). Modified Yi Guan Jian, a Chinese herbal formula, induces anoikis in Bel-7402 human hepatocarcinoma cells in vitro. Oncol. Rep. 26, 1465–1470. doi: 10.3892/or.2011.1414
Hu, B., Zhang, T., An, H. M., Zheng, J. L., Yan, X., Huang, X. W. (2018). Herbal formula YGJDSJ inhibits anchorage-independent growth and induces anoikis in hepatocellular carcinoma Bel-7402 cells. BMC Complement Altern. Med. 18, 17. doi: 10.1186/s12906-018-2083-2
Huang, Y., Zhu, J., Lin, X., Hong, Y., Feng, Y., Shen, L. (2019). Potential of Fatty Oils from Traditional Chinese Medicine in Cancer Therapy: A Review for Phytochemical, Pharmacological and Clinical Studies. Am. J. Chin Med. 47, 727–750. doi: 10.1142/S0192415X19500381
Kim, H., Jang, E., Kim, S. Y., Choi, J. Y., Lee, N. R., Kim, D. S., et al. (2018). Preclinical Evaluation of In Vitro and In Vivo Antiviral Activities of KCT-01, a New Herbal Formula against Hepatitis B Virus. Evid. Based Complement Alternat. Med. 2018, 1073509. doi: 10.1155/2018/1073509
Lee, H. J., Lee, E. O., Rhee, Y. H., Ahn, K. S., Li, G. X., Jiang, C., et al. (2006). An oriental herbal cocktail, ka-mi-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis and metastasis. Carcinogenesis 27, 2455–2463. doi: 10.1093/carcin/bgl104
Lee, M. Y., Lin, H. Y., Cheng, F., Chiang, W., Kuo, Y. H. (2008). Isolation and characterization of new lactam compounds that inhibit lung and colon cancer cells from adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) bran. Food Chem. Toxicol. 46, 1933–1939. doi: 10.1016/j.fct.2008.01.033
Li, L., Yin Tang, L., Liang, B., Wang, R., Sun, Q., Bik San Lau, C., et al. (2019). Evaluation of in vitro embryotoxicity tests for Chinese herbal medicines. Reprod. Toxicol. 89, 45–53. doi: 10.1016/j.reprotox.2019.06.001
Li, S. S. (2019). Experience of Simo Decoction Combined with Acupoint Massage in the Treatment of Gastrointestinal Dysfunction of Primary Liver Cancer. Chin. Med. Modern Distance Educ. China 17, 50. doi: 10.3969/j.issn.1672-2779.2019.08.021
Lin, C. C., Ng, L. T., Hsu, F. F., Shieh, D. E., Chiang, L. C. (2004). Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth. Clin. Exp. Pharmacol. Physiol. 31, 65–69. doi: 10.1111/j.1440-1681.2004.03951.x
Lin, W., Zhuang, Q., Zheng, L., Cao, Z., Shen, A., Li, Q., et al. (2015). Pien Tze Huang inhibits liver metastasis by targeting TGF-beta signaling in an orthotopic model of colorectal cancer. Oncol. Rep. 33, 1922–1928. doi: 10.3892/or.2015.3784
Liu, Q., Zhang, Y. B., Ma, C. H., Yue, X. Q., Ling, C. Q. (2005). [Analysis of literature on therapeutic methods and medicines of traditional Chinese medicine for primary liver cancer]. Zhong Xi Yi Jie He Xue Bao 3, 260–262. doi: 10.3736/jcim20050403
Liu, J., Wang, S., Zhang, Y., Fan, H. T., Lin, H. S. (2015). Traditional Chinese medicine and cancer: History, present situation, and development. Thorac. Cancer 6, 561–569. doi: 10.1111/1759-7714.12270
Liu, Z., Tian, X., Cheng, L. (2016). Effect of Modified Shuangbai Powder Combined with Three-Step Method Analgesic on Patients with Primary Hepatic Cancer Pain. Zhong Yi Yao Dao Bao 22, 45. doi: CNKI:SUN:HNZB.0.2016-23-015
Lu, G. D., Shen, H. M., Chung, M. C., Ong, C. N. (2007). Critical role of oxidative stress and sustained JNK activation in aloe-emodin-mediated apoptotic cell death in human hepatoma cells. Carcinogenesis 28, 1937–1945. doi: 10.1093/carcin/bgm143
Peng, J. X., He, J. M., Cai, B. Q., Chen, G. H., Liu, M. (2018). Study on the effect of Fuzheng Yiliu Decoction on invasion and metastasis of hepatocellular carcinoma cells. China Med. Herald 15, 25. doi: CNKI:SUN:YYCY.0.2018-10-007
Qi, F., Zhou, S., Li, L., Wei, L., Shen, A., Liu, L., et al. (2017). Pien Tze Huang inhibits the growth of hepatocellular carcinoma cells by upregulating miR-16 expression. Oncol. Lett. 14, 8132–8137. doi: 10.3892/ol.2017.7240
Roxas, M., Jurenka, J. (2007). Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Altern. Med. Rev. 12, 25–48. doi: 10.1016/j.jep.2006.09.034
Ruchita, S., Nanda, S., Pathak, D. (2017). Analgesic Prodrugs for Combating their Side-Effects: Rational Approach. Curr. Drug Deliv. 14, 16–26. doi: 10.2174/1567201813666160504100705
Saif, M. W., Lansigan, F., Ruta, S., Lamb, L., Mezes, M., Elligers, K., et al. (2010). Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine 17, 161–169. doi: 10.1016/j.phymed.2009.12.016
Shay, G., Lynch, C. C., Fingleton, B. (2015). Moving targets: Emerging roles for MMPs in cancer progression and metastasis. Matrix Biol., 44–46, 200–206. doi: 10.1016/j.matbio.2015.01.019
Shen, L. X., Wang, M. B., Zhang, H. Y. (2014). Clinical observation on therapeutic effect of Xiaotongsan combined with morphine sustained release tablets in treating late-stage liver cancer pain patients. Zhong Xi Yi Jie He Gan Bing Za Zhi 24, 267. doi: 10.3969/j.issn.1005-0264.2014.05.004
Sherman, M. (2008). Recurrence of hepatocellular carcinoma. N Engl. J. Med. 359, 2045–2047. doi: 10.1056/NEJMe0807581
Siegel, R. L., Miller, K. D., Jemal, A. (2017). Cancer Statistics 2017. CA Cancer J. Clin. 67, 7–30. doi: 10.3322/caac.21387
Song, P., Wu, J. (2017). Effect of Huangqi Sijunzi Decoction Combined with Blood Component Transfusion on Postoperative Immune Function in Patients with Liver Cancer. China Med. Herald 23, 50. doi: 10.ssss/j.issn.1672-951X.2017.21.015
Sui, H., Liu, X., Jin, B. H., Pan, S. F., Zhou, L. H., Yu, N. A., et al. (2013). Zuo Jin Wan, a Traditional Chinese Herbal Formula, Reverses P-gp-Mediated MDR In Vitro and In Vivo. Evid. Based Complement Alternat. Med. 2013, 957078. doi: 10.1155/2013/957078
Tang, Q. F., Liu, X., Ge, Y. (2012). Experimental study on inhibiting proliferation and inducing apoptosis of zuo jin wan alcohol extracts on human gastric cancer cells infected by Helicobacter pylori. Chongqing Med. 41, 1462.
Tao, C., Dan, L., Ling, F., Peng, G. (2010). In vivo and in vitro effects of QHF combined with chemotherapy on hepatocellular carcinoma. J. BioMed. Res. 24, 161–168. doi: 10.1016/S1674-8301(10)60025-5
Tao, L., Yang, J. K., Gu, Y., Zhou, X., Zhao, A. G., Zheng, J., et al. (2015a). Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model. World J. Gastroenterol. 21, 1125–1139. doi: 10.3748/wjg.v21.i4.1125
Tao, W., Luo, X., Cui, B., Liang, D., Wang, C., Duan, Y., et al. (2015b). Practice of traditional Chinese medicine for psycho-behavioral intervention improves quality of life in cancer patients: A systematic review and meta-analysis. Oncotarget 6, 39725–39739. doi: 10.18632/oncotarget.5388
Trefts, E., Gannon, M., Wasserman, D. H. (2017). The liver. Curr. Biol. 27, R1147–R1151. doi: 10.1016/j.cub.2017.09.019
Wan, Y., Shen, A., Qi, F., Chu, J., Cai, Q., Sferra, T. J., et al. (2017). Pien Tze Huang inhibits the proliferation of colorectal cancer cells by increasing the expression of miR-34c-5p. Exp. Ther. Med. 14, 3901–3907. doi: 10.3892/etm.2017.4972
Wang, N., Zhu, M., Wang, X., Tan, H. Y., Tsao, S. W., Feng, Y. (2014). Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim. Biophys. Acta 1839, 849–857. doi: 10.1016/j.bbagrm.2014.05.027
Wang, N., Feng, Y., Tan, H. Y., Cheung, F., Hong, M., Lao, L., et al. (2015a). Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma. J. Ethnopharmacol 164, 309–318. doi: 10.1016/j.jep.2015.02.025
Wang, N., Tan, H. Y., Li, L., Yuen, M. F., Feng, Y. (2015b). Berberine and Coptidis Rhizoma as potential anticancer agents: Recent updates and future perspectives. J. Ethnopharmacol 176, 35–48. doi: 10.1016/j.jep.2015.10.028
Wang, X., Yang, Y., Yang, X. W. (2019). Therapeutic Effect of Dachaihu Decoction on Postoperative Syndrome of Hepatocellular Carcinoma after TACE. J. Shananxi Univ. Chin. Med. 42, 130. doi: 10.13424/j.cnki.jsctcm.2019.01.039
Wei, F., Lang, Y., Gong, D., Fan, Y. (2015). Effect of Dahuang zhechong formula on liver fibrosis in patients with chronic hepatitis B: a meta-analysis. Complement Ther. Med. 23, 129–138. doi: 10.1016/j.ctim.2014.12.011
Wu, Y. F., Wang, S. P., Sun, J. M., Wei, J. N. (2007). Clinical distribution and standards of TCM Syndrome of primary hepatic carcinoma. Shanxi Coll. Tradit Chin. Med. 8, 21.
Xi, S., Hong, R., Huang, J., Lu, D., Qian, L., Li, P., et al. (2014). Effects of Ciji Hua'ai Baosheng granule formula (CHBGF) on life time, pathology, peripheral blood cells of tumor chemotherapy model mouse with H22 hepatoma carcinoma cells. Afr J. Tradit Complement Altern. Med. 11, 94–100. doi: 10.4314/ajtcam.v11i4.16
Xi, S., Peng, Y., Minuk, G. Y., Shi, M., Fu, B., Yang, J., et al. (2016). The combination effects of Shen-Ling-Bai-Zhu on promoting apoptosis of transplanted H22 hepatocellular carcinoma in mice receiving chemotherapy. J. Ethnopharmacol 190, 1–12. doi: 10.1016/j.jep.2016.05.055
Xi, S., Fu, B., Loy, G., Minuk, G. Y., Peng, Y., Qiu, Y., et al. (2018). The effects of Ciji-Hua'ai-Baosheng on immune function of mice with H22 hepatocellular carcinoma receiving chemotherapy. BioMed. Pharmacother. 101, 898–909. doi: 10.1016/j.biopha.2018.03.027
Xia, B. (1989). Application of GSBXT in treatment of liver cancer. Shanxi J. Tradit. Chin. Med. 5, 24.
Xu, Y. X., Xiang, Z. B., Jin, Y. S., Shen, Y., Chen, H. S. (2010). Two new triterpenoids from the roots of Actinidia chinensis. Fitoterapia 81, 920–924. doi: 10.1016/j.fitote.2010.06.007
Xu, Y., Zhao, A. G., Li, Z. Y., Zhao, G., Cai, Y., Zhu, X. H., et al. (2013). Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer. Integr. Cancer Ther. 12, 414–422. doi: 10.1177/1534735412450512
Xu, L., Qi, Y., Lv, L., Xu, Y., Zheng, L., Yin, L., et al. (2014). In vitro anti-proliferative effects of Zuojinwan on eight kinds of human cancer cell lines. Cytotechnology 66, 37–50. doi: 10.1007/s10616-013-9534-x
Yang, Y., Yang, S., Chen, M., Zhang, X., Zou, Y., Zhang, X. (2008). Compound Astragalus and Salvia miltiorrhiza Extract exerts anti-fibrosis by mediating TGF-beta/Smad signaling in myofibroblasts. J. Ethnopharmacol 118, 264–270. doi: 10.1016/j.jep.2008.04.012
Yen, Y., So, S., Rose, M., Saif, M. W., Chu, E., Liu, S. H., et al. (2009). Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res. 29, 4083–4092.
Yu, Y., Lang, Q., Chen, Z., Li, B., Yu, C., Zhu, D., et al. (2009). The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer 115, 5132–5138. doi: 10.1002/cncr.24567
Zeng, L., Tang, G., Wang, J., Zhong, J., Xia, Z., Li, J., et al. (2019). Safety and efficacy of herbal medicine for acute intracerebral hemorrhage (CRRICH): a multicentre randomised controlled trial. BMJ Open 9, e024932. doi: 10.1136/bmjopen-2018-024932
Zhang, J., Wang, P., Ouyang, H., Yin, J., Liu, A., Ma, C., et al. (2013). Targeting cancer-related inflammation: Chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. PLoS One 8, e70334. doi: 10.1371/journal.pone.0070334
Zhang, Y., Guo, X., Wang, D., Li, R., Li, X., Xu, Y., et al. (2014). A systems biology-based investigation into the therapeutic effects of Gansui Banxia Tang on reversing the imbalanced network of hepatocellular carcinoma. Sci. Rep. 4, 4154. doi: 10.1038/srep04154
Zhang, Q. B., Meng, X. T., Jia, Q. A., Bu, Y., Ren, Z. G., Zhang, B. H., et al. (2016). Herbal Compound Songyou Yin and Moderate Swimming Suppress Growth and Metastasis of Liver Cancer by Enhancing Immune Function. Integr. Cancer Ther. 15, 368–375. doi: 10.1177/1534735415622011
Zhang, J. Z., Feng, X. W., Meng, F. P. (2017). Effect of Fuzheng Jiedu Tongluofang on MMP-2 and MMP-9 and invasion of human hepatoma HepG2 cells. Zhong Guo Mian Yi Xue Za Zhi 33, 542. doi: 10.3969/j.issn.1000-484X.2017.04.013
Zhang, X. T. (2019). Clinical effect of addition and subtraction of Dachaihu Decoction and Liujunzi Decoction in the treatment of post-embolization syndrome of liver cancer. China Modern Med. 26, 89. doi: 10.3969/j.issn.1674-4721.2019.05.028
Zhao, A. G., Cao, W., Xu, Y., Zhao, G., Liu, B. Y., Cai, Y., et al. (2010). [Survival benefit of an herbal formula for invigorating spleen for elderly patients with gastric cancer]. Zhong Xi Yi Jie He Xue Bao 8, 224–230. doi: 10.3736/jcim20100305
Zhao, W. J., Zhao, D. M., Zhang, Z. (2011). Treatment Efficacy of 25 Cases of Primary Liver Cancer Treatrd by YangGan HuaYu KangAiSan. Western J. Traditional Chin. Med. 24, 8. doi: 10.3969/j.issn.1674-7860.2017.08.026
Zhou, X. Y., Su, B. H., Zhang, Y. Y., Zhai, Y. J. (2012). [Effects of different processing on active components in fructus polygoni orientalis by HPLC analysis]. Zhong Yao Cai 35, 540–542.
Zhou, X., Wang, A., Wang, L., Yin, J., Wang, L., Di, L., et al. (2019). A Danshensu-Tetramethylpyrazine Conjugate DT-010 Overcomes Multidrug Resistance in Human Breast Cancer. Front. Pharmacol. 10, 722. doi: 10.3389/fphar.2019.00722
Keywords: cancer, liver cancer, hepatocellular carcinoma, Chinese herbal medicine formula, alternative therapy
Citation: Chen F, Zhong Z, Tan HY, Guo W, Zhang C, Tan C-w, Li S, Wang N and Feng Y (2020) Uncovering the Anticancer Mechanisms of Chinese Herbal Medicine Formulas: Therapeutic Alternatives for Liver Cancer. Front. Pharmacol. 11:293. doi: 10.3389/fphar.2020.00293
Received: 07 October 2019; Accepted: 27 February 2020;
Published: 18 March 2020.
Edited by:
Anthony Booker, University of Westminster, United KingdomReviewed by:
Ling Yang, Shanghai University of Traditional Chinese Medicine, ChinaChi Chiu Wang, The Chinese University of Hong Kong, Hong Kong
Copyright © 2020 Chen, Zhong, Tan, Guo, Zhang, Tan, Li, Wang and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yibin Feng, yfeng@hku.hk